Compare EWBC & INCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EWBC | INCY |
|---|---|---|
| Founded | 1998 | 1991 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Commercial Physical & Biological Resarch |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.9B | 17.0B |
| IPO Year | 1999 | 1993 |
| Metric | EWBC | INCY |
|---|---|---|
| Price | $110.11 | $102.46 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 12 | 20 |
| Target Price | ★ $124.00 | $90.71 |
| AVG Volume (30 Days) | 525.6K | ★ 2.0M |
| Earning Date | 01-22-2026 | 10-28-2025 |
| Dividend Yield | ★ 2.18% | N/A |
| EPS Growth | 14.57 | ★ 3878.02 |
| EPS | ★ 9.07 | 5.90 |
| Revenue | $2,572,339,000.00 | ★ $4,813,105,000.00 |
| Revenue This Year | $8.44 | $19.59 |
| Revenue Next Year | $7.04 | $10.88 |
| P/E Ratio | ★ $12.17 | $17.37 |
| Revenue Growth | 6.63 | ★ 18.09 |
| 52 Week Low | $68.27 | $53.56 |
| 52 Week High | $110.80 | $109.28 |
| Indicator | EWBC | INCY |
|---|---|---|
| Relative Strength Index (RSI) | 66.17 | 54.83 |
| Support Level | $105.70 | $100.55 |
| Resistance Level | $108.47 | $107.61 |
| Average True Range (ATR) | 2.79 | 2.94 |
| MACD | 0.67 | -0.98 |
| Stochastic Oscillator | 99.23 | 45.19 |
East West Bancorp Inc operates in U.S. and Asia. The Bank provides range of personal and commercial banking services to individuals and businesses. In addition to offering traditional deposit products that include personal and business checking and savings accounts, money market, and time deposits, the Bank also offers foreign exchange, treasury management and wealth management services. The Bank has three operating segments, (1) Consumer and Business Banking, (2) Commercial Banking and (3) Treasury and Other. The company generates the majority of its revenue from the Commercial banking segment.
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.